About Exophilin-5
Exophilin-5 (EXPH5) is a protein
from Homo sapiens identified by UniProt accession
Q8NEV8, 1989 residues long.
MolForge cross-references it against 0 known binders and
61 disease associations.
Target properties
| Protein name | Exophilin-5 |
|---|
| UniProt accession | Q8NEV8 |
|---|
| Gene | EXPH5 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1989 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (61)
Diseases linked to this target (Open Targets).
- epidermolysis bullosa simplex 4, localized or generalized intermediate, autosomal recessive · score 0.73
- genetic disorder · score 0.42
- epidermolysis bullosa simplex · score 0.37
- serum alanine aminotransferase measurement · score 0.37
- blood protein measurement · score 0.19
- lymphocyte count · score 0.15
- platelet crit · score 0.12
- platelet count · score 0.10
- Headache · score 0.04
- nephrogenic syndrome of inappropriate antidiuresis · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8NEV8-F1 | alphafold | PREDICTED | 36.12 | — |
Amino-acid sequence (1989 residues)
MTKVPPAFDF SFLNDEEARK ILQVLERNEE LQRAEKDRIS KLQKTKRDIR WLQGVTGEWF EEIQRKKFCN ETDVSQMLKQ PLTYRLSKEM AKNDPIELPT SRSKNVTNQK KPTPFSSRMS FRSSFASLFS FRKSGKETSK LPSLGQKGCD GHAGPPMPVR GAAVQAKIYN SPLENHLVDS TFVPKPAVMR EESGMPPPWD ASLLENEFFQ VLDDLDSKLA QEQSASSVNT RTPLNYGSRT QFGHFYSSGN RHGNITERHK KHYNETSNMS IYDILRPGTP REGFKTFSPR TSTIYDMYRT REPRVFKEDY VQKNTFGSTS LCFDSRQRSA LPATGHFTAR SLHFPATTQS KSGFIPPRHQ QSPKRTPLSS IIWNRSDSSR DRENQEEFLR APSPMEIDPA DKYVYPRGFQ ENKRYESYHS QNVYQRVSLN APMENAMSPD TFENSENMPF YHQSNTFTRS FFSNTFGRSG EQRRFGQGPF WGQEKGHSFW SDFHRSRKSF SSSDRDFEMI SMEANSVSAI HGHNVSSEHW ESFSSGYGTD VSRGQEEPHP WQFDFQRSTL DSMVVSHGNE TQLTPHFGTP NVCSMTGSSY HVKSSELVSQ QDSSPVEVHI NKEASSFGIA QTLASSFKTS FSQISDDRRN PQSPNLQNPT VTLQKIFPNK PASHPMRSHT EVTVTSSNSV DSLPLAKSQP NILVTEVNNE KDLNESISEE DKQLSKMDQT NKAGEIPQPV SQTGISNSLP DFQNPLSQDS AKSNGFGFNA STIISSKKSP RVFSRKDTSK MYIPHTDKSN DIKQDKRFTE NRKLGSTASL PFIQEHRTPP SFPRTDQGCH QELTVNNEDI SRIITNNHWS SALTDTQNAQ YSKCKLTPGH KTSCDSLDLS SAALPDSSPS KNSSLDAPVV PSTTVFSRRS PSDKDPSLGE REEKDNAGKN QKNQFIVSHS ENQERNDSPV PTHDEVVDVK CHSHSPFRNE RGKGKIRHHI SCIEKLSKTE SISVPTSDHR SLIEANQSNS KVSELDTIYC TLPRKSSSFL IHGRQSGSKI MAASLRNGPP PFQIKNNVED AMGNYMLNKF SPSSPESANE CSKVLSDSAL EAPEATERMT NVKSSGSTSV RKGPLPFLIN RAMSCPSGEP HASTGREGRK KPLTSGMDAS ELTPRAWERI ISPVESDSSV RDCSLTKRQH QKENFQEYTE KEGKMAASRR SVFALSNEDP LPFCSDLSGK ERGKTLHKVK TTSTFSVSGD EDNVKCLEVV SIYYTLPRKP SKKFCNLLQQ YTQNTNLLIE SPQVETETFP NALEKDKQNY STREQSGTPS CENLKMSVNS DQTLTTENMT AFRLSNRGPL APTLQEMASV EAAVSLPEEE SKAREIFSDN LAKTPLGDSE NKKERGKKLQ SETLHTSLML QRKNVSEEKS ENCQQSINSS NSGPSSLPAL SEVNIGNSQT RRSSWECTGS GRAIPFTGSG KCPQKDHTST AVGDGSSGSQ PREGRGDIGT NCQKMTNKTL SHSESQVFAL TPALHKLQLG EETQSDEPNL ESLQSEPREL PQRSQEANMT ESRKAEDEMQ KSAWDQPSLP EGNKNKTNLD DLVKGENRSS VKHRLAAMSK ASRKFPAKDV SPRRHVATIF PQSGSRSGFD HLSLGTVECN PLFPEPTPKS AESIGESRLS ENGKHVKKSE NLLPITVLPN REPSTHVSNQ KSNSISQRHQ NEFKNVSESP SKHENSKDVT AAQNLVRESG APSPITFTSL REAEFSDNQR RLSPPFPLEP AQKSRVSSPL ASFLQQQRSA SSLEWEPEPH LYRSKSLKSI NVHGDLLRKS HPPKVRERHF SESTSIDNAL SRLTLGNEFS VNNGYSRRFR SFSELPSCDG NESWAYRSGT KTGPRSAISI YRPIDYGIFG KEQQLAFLEN VKRSLTQGRL WKPSFLKNPG FLKDDLRNPP NPSESLSSNS PSSQVPEDGL SPSEPLNIYE DDPVDSDCDT DTTTDDEYYL DENDKESEL
Explore Exophilin-5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets